

## **AMENDMENTS TO THE CLAIMS**

This listing of claims will replace all prior versions and listings of claims in the application.

### **Listing of Claims:**

1. (Cancelled).
2. (Cancelled).
3. (Previously presented) An anti-cancer composition comprising an antigen, an effective amount of at least one immunomodulator chemotherapeutic compound and a pharmaceutically acceptable carrier, said composition eliciting an immune response in a patient and wherein said antigen is inactivated tumor cells from a cancer targeted by said anti-cancer composition.
4. (Previously presented) The anti-cancer composition of claim 3, wherein said antigen is tumor cells inactivated by said chemotherapeutic compound.
5. (Previously presented) The anti-cancer composition of claim 3, wherein said tumor cells are inactivated by radiotherapy and/or chemotherapy.
6. (Previously presented) The anti-cancer composition of claim 3, wherein said tumor cells are inactivated by radiotherapy.
7. (Previously presented) The anti-cancer composition of any one of claims 3-6, wherein said composition is eliciting an immunoprotective response against a cancer selected from the group consisting of basal cell carcinoma, bladder cancer, bone cancer, brain cancer, CNS cancer, breast cancer, cervical cancer, colon cancer, rectum cancer, connective tissue cancer, esophageal cancer, eye cancer, kidney cancer, larynx cancer, liver cancer, lung cancer, Hodgkin's lymphoma, non-Hodgkin's lymphoma, melanoma, myeloma, leukemia, oral cavity cancer, ovarian cancer, pancreatic cancer, prostate cancer, rhabdomyosarcoma, skin cancer, stomach cancer, testicular cancer, neoplasia and uterine cancer.
8. (Previously presented) The anti-cancer composition of any one of claims 3-6, wherein said composition is eliciting an immune response against a cancer selected from the

group consisting of bladder cancer, prostate cancer, melanoma, breast cancer, colon cancer, lung cancer, liver cancer, lymphoma, myeloma, leukemia and ovarian cancer.

9. (Previously presented) The anti-cancer composition of claim 3, wherein said chemotherapeutic compound is a taxane.

10. (Previously presented) The anti-cancer composition of claim 3, wherein said chemotherapeutic compound is selected from the group consisting of Cyclophosphamide, Doxorubicin, Cisplatin, Paclitaxel and 5-fluorouracil.

11. (Previously presented) The anti-cancer composition of any one of claim 3-10, further comprising a therapeutically effective amount of a therapeutic agent.

12. (Previously presented) The anti-cancer composition of claim 11, wherein said therapeutic agent is selected from the group consisting of cytokine, antibody, systemic chemotherapeutic agent, biological response modifier and hormones.

13. (Cancelled).

14. (Previously presented) The anti-cancer composition of claim 12, wherein said biological response modifier is selected from the group consisting of interferon and lymphokine.

15. (Previously presented) The anti-cancer composition of claim 14, wherein said lymphokine is IL-2.

16. (Previously presented) The anti-cancer composition of any one of claims 3-12 and 14-15, further comprising a non-chemotherapeutic adjuvant selected from the group consisting of polysaccharides, CpG nucleic acids, MF59, SAF, MPL and QS21.

17. (Previously presented) The anti-cancer composition of any one of claims 3-12 and 14-16, further comprising a non-chemotherapeutic compound selected from the group consisting of compounds that create a local reservoir of drug, compounds that stimulate the immune system, mucosal compounds, phosphazene and *Leishmania* elongation factor.

18-38. (Cancelled).